1. Home
  2. AMWD vs LBRX Comparison

AMWD vs LBRX Comparison

Compare AMWD & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$38.86

Market Cap

872.8M

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

SELL

Current Price

$28.07

Market Cap

850.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AMWD
LBRX
Founded
1980
2015
Country
United States
United States
Employees
N/A
27
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
850.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
AMWD
LBRX
Price
$38.86
$28.07
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$59.50
$46.60
AVG Volume (30 Days)
259.6K
127.7K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,709,585,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$33.29
$13.40
52 Week High
$72.16
$33.47

Technical Indicators

Market Signals
Indicator
AMWD
LBRX
Relative Strength Index (RSI) 48.02 43.90
Support Level $36.48 $22.39
Resistance Level $42.58 $33.47
Average True Range (ATR) 2.02 1.66
MACD 0.07 -0.67
Stochastic Oscillator 58.11 25.25

Price Performance

Historical Comparison
AMWD
LBRX

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: